{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:06:03Z","timestamp":1788231963682,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00415-026-13879-x","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:49:21Z","timestamp":1779176961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world outcomes and early discontinuation of foslevodopa\/foscarbidopa in Parkinson\u2019s disease"],"prefix":"10.1007","volume":"273","author":[{"given":"Takashi","family":"Tsuboi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuo","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Ikenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Kajiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Kamiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Uematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Kakuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Mihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Shindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyoshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahisa","family":"Katsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"13879_CR1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS (2020) Diagnosis and treatment of Parkinson disease: a review. JAMA 323:548\u2013560","journal-title":"JAMA"},{"key":"13879_CR2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00702-025-02990-4","volume":"133","author":"M Regensburger","year":"2026","unstructured":"Regensburger M, Csoti I, Jost WH et al (2026) Motor and non-motor fluctuations in Parkinson\u2019s disease: the knowns and unknowns of current therapeutic approaches. J Neural Transm (Vienna) 133:309\u2013324","journal-title":"J Neural Transm (Vienna)"},{"key":"13879_CR3","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K et al (2022) Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 21:1099\u20131109","journal-title":"Lancet Neurol"},{"key":"13879_CR4","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","author":"J Aldred","year":"2023","unstructured":"Aldred J, Freire-Alvarez E, Amelin AV et al (2023) Continuous subcutaneous foslevodopa\/foscarbidopa in Parkinson\u2019s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurol Ther 12:1937\u20131958","journal-title":"Neurol Ther"},{"key":"13879_CR5","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1002\/mdc3.70249","volume":"12","author":"K Rukavina","year":"2025","unstructured":"Rukavina K, Ebersbach G, Gruber D (2025) Foslevodopa\/foscarbidopa continuous subcutaneous infusion in Parkinson\u2019s disease: real-world short-term data on tolerability, infusion rate adjustments and concomitant medication. Mov Disord Clin Pract 12:2317\u20132323","journal-title":"Mov Disord Clin Pract"},{"key":"13879_CR6","doi-asserted-by":"publisher","first-page":"1619850","DOI":"10.3389\/fnagi.2025.1619850","volume":"17","author":"A Jander","year":"2025","unstructured":"Jander A, Bergner S, Sch\u00f6nwald B et al (2025) Subcutaneous foslevodopa\/foscarbidopa initiation in a Parkinson\u2019s day-clinic - a suitable setting to ensure treatment efficacy, tolerability and psychosocial adaption. Front Aging Neurosci 17:1619850","journal-title":"Front Aging Neurosci"},{"key":"13879_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-025-03066-z","author":"D Santos-Garc\u00eda","year":"2025","unstructured":"Santos-Garc\u00eda D, Solleiro \u00c1, Gonz\u00e1lez-Ortega G et al (2025) Impact of device-aided therapies on quality of life in patients with Parkinson\u2019s disease. A comparative multicenter observational study. J Neural Transm (Vienna). https:\/\/doi.org\/10.1007\/s00702-025-03066-z","journal-title":"J Neural Transm (Vienna)"},{"key":"13879_CR8","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200534","volume":"15","author":"L Ge","year":"2025","unstructured":"Ge L, Kimura Y, Kakuda K et al (2025) Atypical psychosis in Parkinson disease: a retrospective study on 24-hour continuous subcutaneous infusion of foslevodopa\/foscarbidopa. Neurol Clin Pract 15:e200534","journal-title":"Neurol Clin Pract"},{"key":"13879_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70397","author":"M Bradley","year":"2025","unstructured":"Bradley M, Coran M, Donlon E et al (2025) Foslevodopa\/foscarbidopa continuous subcutaneous infusion in Parkinson\u2019s disease: extended real world data with outpatient dose titration. Mov Disord Clin Pract. https:\/\/doi.org\/10.1002\/mdc3.70397","journal-title":"Mov Disord Clin Pract"},{"key":"13879_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70448","author":"B Pinna","year":"2025","unstructured":"Pinna B, Fenu G, Mellino P et al (2025) Titration dynamics and early treatment burden in advanced Parkinson\u2019s disease: a multicenter comparison of CSFLI and LCIG infusion therapies. Mov Disord Clin Pract. https:\/\/doi.org\/10.1002\/mdc3.70448","journal-title":"Mov Disord Clin Pract"},{"key":"13879_CR11","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/mdc3.70060","volume":"12","author":"S Broh\u00e9e","year":"2025","unstructured":"Broh\u00e9e S, Roze E, Grabli D et al (2025) Cognitive and psychiatric adverse effects of foslevodopa\/foscarbidopa in patients with Parkinson\u2019s disease. Mov Disord Clin Pract 12:1028\u20131030","journal-title":"Mov Disord Clin Pract"},{"key":"13879_CR12","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1002\/mdc3.70254","volume":"12","author":"C Desjardins","year":"2025","unstructured":"Desjardins C, Salardaine Q, Brandel J-P, Baille G (2025) Clinical impact of switching from subcutaneous apomorphine to foslevodopa\/foscarbidopa in advanced Parkinson\u2019s disease: a real-world observational study (FOSAPO). Mov Disord Clin Pract 12:2330\u20132336","journal-title":"Mov Disord Clin Pract"},{"key":"13879_CR13","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/mds.29410","volume":"38","author":"ST Jost","year":"2023","unstructured":"Jost ST, Kaldenbach M-A, Antonini A et al (2023) Levodopa dose equivalency in Parkinson\u2019s disease: updated systematic review and proposals. Mov Disord 38:1236\u20131252","journal-title":"Mov Disord"},{"key":"13879_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.parkreldis.2018.08.018","volume":"58","author":"A Makkos","year":"2019","unstructured":"Makkos A, Kov\u00e1cs M, Pint\u00e9r D et al (2019) Minimal clinically important difference for the historic parts of the Unified Dyskinesia Rating Scale. Parkinsonism Relat Disord 58:79\u201382","journal-title":"Parkinsonism Relat Disord"},{"key":"13879_CR15","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/mds.26960","volume":"32","author":"K Horv\u00e1th","year":"2017","unstructured":"Horv\u00e1th K, Aschermann Z, Kov\u00e1cs M et al (2017) Minimal clinically important differences for the experiences of daily living parts of Movement Disorder Society-sponsored Unified Parkinson\u2019s Disease Rating Scale. Mov Disord 32:789\u2013793","journal-title":"Mov Disord"},{"key":"13879_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2025.108142","volume":"143","author":"A Cocco","year":"2026","unstructured":"Cocco A, Zangaglia R, Belluscio G et al (2026) Initiating foslevodopa infusion in Parkinson disease: a pragmatic study. Parkinsonism Relat Disord 143:108142","journal-title":"Parkinsonism Relat Disord"},{"key":"13879_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000455863","volume":"48","author":"K Horv\u00e1th","year":"2017","unstructured":"Horv\u00e1th K, Aschermann Z, Kov\u00e1cs M et al (2017) Changes in quality of life in Parkinson\u2019s disease: how large must they be to be relevant? Neuroepidemiology 48:1\u20138","journal-title":"Neuroepidemiology"},{"key":"13879_CR18","doi-asserted-by":"publisher","DOI":"10.14802\/jmd.25304","author":"C Desjardins","year":"2026","unstructured":"Desjardins C, de Vaulry HS, Salardaine Q et al (2026) Neuropsychiatric and cognitive safety of subcutaneous foslevodopa\/foscarbidopa in advanced Parkinson\u2019s disease: insights from a real-world cohort. J Mov Disord. https:\/\/doi.org\/10.14802\/jmd.25304","journal-title":"J Mov Disord"},{"key":"13879_CR19","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s00415-025-13123-y","volume":"272","author":"M Soileau","year":"2025","unstructured":"Soileau M, Kumar R, Parab A et al (2025) Patients\u2019 experience with and perspectives on long-term use of continuous subcutaneous infusion of foslevodopa\/foscarbidopa in Parkinson\u2019s disease. J Neurol 272:416","journal-title":"J Neurol"},{"key":"13879_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2025.107896","volume":"136","author":"N Nishikawa","year":"2025","unstructured":"Nishikawa N, Hatano T, Kamiyama D et al (2025) Predictors of discontinuation in foslevodopa\/foscarbidopa therapy for Parkinson\u2019s disease. Parkinsonism Relat Disord 136:107896","journal-title":"Parkinsonism Relat Disord"},{"key":"13879_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00702-025-02911-5","volume":"133","author":"T Koeglsperger","year":"2026","unstructured":"Koeglsperger T, Berberovic E, Dresel C et al (2026) Real-world experience with continuous subcutaneous foslevodopa\/foscarbidopa infusion: insights and recommendations. J Neural Transm (Vienna) 133:347\u2013359","journal-title":"J Neural Transm (Vienna)"},{"key":"13879_CR22","volume":"10","author":"VSC Fung","year":"2024","unstructured":"Fung VSC, Aldred J, Arroyo MP et al (2024) Continuous subcutaneous foslevodopa\/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson\u2019s disease: considerations for initiation and maintenance. Clin Park Relat Disord 10:100239","journal-title":"Clin Park Relat Disord"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13879-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13879-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13879-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T17:09:57Z","timestamp":1781370597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13879-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["13879"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13879-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.T. has received honoraria for lectures from AbbVie, Eisai, Kyowa Kirin, Ono Pharmaceutical, and Takeda Pharmaceutical. K. Kimura has received honoraria for lectures from Abbott, AbbVie, Boston Scientific, Eisai, FP Pharmaceutical, Medtronic, Ono Pharmaceutical, and Takeda Pharmaceutical. K.I. has received honoraria for lectures from Eisai, FP, and AbbVie. T.B. has received research grants from Nihon Medi-physics and honoraria for lectures from Ono Pharmaceutical, AbbVie, Kyowa Kirin, and Eisai. K. Matsuura has received honoraria for lectures from Eisai, Ono Pharmaceutical, Daiichi Sankyo, Kyowa Kirin, Kowa, Novartis Pharma, UCB Japan, AbbVie, TEIJIN HOME HEALTHCARE, Boston Scientific Japan, and argenx Japan. K.A. has received honoraria for lectures from AbbVie. K. Kakuda has received honoraria for lectures from Ono Pharmaceutical and FP. M.M. has received honoraria from AbbVie, joint research funding from Philosophia, Inc., and equipment from TecDoctor, Inc. A. Shindo has received research grants from Daiichi Sankyo and Eli Lilly and Company, and honoraria for lectures from Eisai, Ono Pharmaceutical, Daiichi Sankyo, Kyowa Kirin, Otsuka Pharmaceutical, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Kowa, Eli Lilly Japan, Alexion Pharmaceuticals, Novartis Pharma, UCB Japan, Chugai Pharmaceutical, and Biogen Japan. T.H. has received honoraria from Takeda Pharma, Ono Pharmaceutical, Sumitomo Pharma, Kyowa Kirin, Eisai, Kowa, PDR Pharma, Orion Pharma, EA Pharma, AbbVie, Boston Scientific, and Abbott Laboratories, and publishing royalties from Igaku-Shoin, Nankodo, and Kagaku-Hyoronsha. Y. Kimura has received honoraria for lectures from AbbVie, Eisai, FP, Ono Pharmaceutical, Takeda Pharmaceutical, TEIJIN HOME HEALTHCARE, and Viatris. F.T. has received collaborative research funding from Sysmex Corporation and honoraria for lectures from Biogen. N.H. has received honoraria for consulting and\/or lectures from Sumitomo Pharma, Ono Pharmaceutical, Takeda Pharmaceutical, Kyowa Kirin, Eisai, Biogen Idec Japan, AbbVie GK, Teijin Pharma, Alexion Pharmaceuticals, Daiichi Sankyo, PARKINSON Laboratories, MEDICOLAB, and Yoda Therapeutics. He holds endowed chairs or receives research support from Sumitomo Pharma, Otsuka Pharmaceutical, Takeda Pharmaceutical, Kyowa Kirin, SUNWELS, Eisai, Nihon Medi-physics, Abbott Japan, AbbVie GK, Medtronic, Boston Scientific Japan, Ono Pharmaceutical, Mitsubishi Tanabe Pharma, ZEBRA, KOWA, PARKINSON Laboratories, and OHARA Pharmaceutical. M.K. has received research grants from Sumitomo Pharma and honoraria for lectures from Eisai. N.N. has received honoraria for lectures from Ono Pharmaceutical, AbbVie GK, and Teijin Pharma, and advisory fees and funding for investigator-initiated clinical research from AbbVie GK. Y. Kajiyama, D.K., T.U., H.T., K. Miyashita, and A. Saito have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study adhered to the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects by the Japanese government. The study protocol was approved by the Osaka University Certified Review Board (approval number: 22311T10-3).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"320"}}